Hu CX, Hu KY, Wang JF. Potential role of the compound Eucommia bone tonic granules in patients with osteoarthritis and osteonecrosis: A retrospective study. World J Clin Cases 2020; 8(1): 46-53 [PMID: 31970169 DOI: 10.12998/wjcc.v8.i1.46]
Corresponding Author of This Article
Jian-Feng Wang, MD, Attending Doctor, Department of Pain, Qilu Hospital of Shandong University, No. 107, Wenhua West Road, Jinan 250012, Shandong Province, China. 18714779474@163.com
Research Domain of This Article
Medicine, Research & Experimental
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jan 6, 2020; 8(1): 46-53 Published online Jan 6, 2020. doi: 10.12998/wjcc.v8.i1.46
Table 1 Comparing the two treatment groups for osteoarthritis
Item
Cure
Effective
Invalid
Total effective rate, %
Eucommia-meloxicam group
12
50
8
88.57
Meloxicam group
7
51
12
82.85
X2
2.126
P value
0.345
Table 2 Comparing the two treatment groups for osteonecrosis
Item
Effective
Invalid
Total effective rate, %
Eucommia-meloxicam group
67
8
89.33
Meloxicam group
55
20
73.33
X2
6.323
P value
0.012
Table 3 Comparison of the WOMAC score in the two groups of osteoarthritis patients
Item
Time
Pain
Stiff
Dysfunction
Eucommia-meloxicam group
Before treatment
13.32 ± 2.12
5.23 ± 1.14
37.23 ± 3.21
After treatment
6.23 ± 1.23
2.38 ± 1.06
23.35 ± 2.31
t
21.266
5.544
69.158
P
0.000
0.000
0.000
Meloxicam group
Before treatment
14.42 ± 2.46
6.16±1.27
36.32 ± 4.17
After treatment
3.69 ± 0.37
1.85 ± 0.26
18.37 ± 3.52
t
30.906
60.655
45.852
P
0.000
0.000
0.000
Comparison of the two groups before treatment
t
9.179
4.418
4.876
P
0.000
0.000
0.000
Comparison of the two groups after treatment
t
21.551
0.74
11.508
P
0.000
0.469
0.000
Table 4 Comparison of the Western Ontario and McMaster Universities Arthritis Index score in the two groups of osteonecrosis
Item
Time
Pain
Stiff
Dysfunction
Eucommia-meloxicam group
Before treatment
16.59 ± 2.13
6.84 ± 0.36
36.63 ± 4.21
After treatment
7.31 ± 3.14
1.69 ± 0.23
17.42 ± 3.58
t
27.141
53.830
52.858
P
0.000
0.000
0.000
Meloxicam group
Before treatment
18.31 ± 3.25
7.82 ± 0.26
35.86 ± 4.36
After treatment
5.16 ± 1.59
2.42 ± 0.19
20.16 ± 3.45
t
25.426
57.876
29.644
P
0.000
0.000
0.000
Comparison of the two groups before treatment
t
8.643
18.094
0.751
P
0.000
0.000
0.453
Comparison of the two groups after treatment
t
11.006
12.114
12.379
P
0.000
0.000
0.000
Table 5 Comparison of the two treatment groups for osteoarthritis
Item
BGP
IL-17
S100A12
SIP
Cysc
SCr
Hb
Eucommia and meloxicam group
Before treatment
2.12 ± 0.12
152 ± 6.13
43 ± 3.2
0.23 ± 0.05
0.83 ± 0.3
46 ± 4.2
132 ± 8.9
After treatment
1.88 ± 0.35
136.44 ± 4.58
36.37 ± 5.68
0.116 ± 0.05
1.12 ± 0.5
63 ± 3.6
113 ± 12.1
t
2.228
6.4
4.008
6.334
3.894
10.17
2.55
P
0.053
0.000
0.003
0.000
0.004
0.000
0.031
Meloxicam group
Before treatment
0.87 ± 0.21
125 ± 6.4
32 ± 6.3
0.11 ± 0.05
0.87 ± 0.43
53 ± 4.9
124 ± 3.6
After treatment
0.64 ± 0.19
104 ± 6.4
18 ± 3.4
0.057 ± 0.01
1.46 ± 0.42
74 ± 5.7
104.3 ± 6.8
t
3.915
7.848
5.609
5.331
3.155
15.374
10.632
P
0.004
0.000
0.000
0.000
0.012
0.000
0.000
Comparison of the two groups before treatment
t
30.644
12.747
5.827
6.357
3.399
7.23
2.215
P
0.000
0.000
0.000
0.000
0.008
0.000
0.054
Comparing the two groups after treatment
t
35.845
14.523
8.409
3.174
2.774
4.97
2.456
P
0.000
0.000
0.000
0.011
0.022
0.000
0.036
Table 6 Comparison of the two treatment groups for osteonecrosis
Item
BGP
IL-17
S100A12
SIP
Cysc
SCr
Hb
Eucommia and meloxicam group
Before treatment
1.95 ± 0.17
142 ± 11.56
65 ± 4.6
0.312 ± 0.06
2.45 ± 0.21
35 ± 5.3
145 ± 6.4
After treatment
1.64 ± 0.15
125.13 ± 13.84
42.7 ± 4.8
0.124 ± 0.04
1.42 ± 0.17
57 ± 3.5
123 ± 4.6
t
2.419
1.432
7.924
9.185
8.175
12.513
6.713
P
0.039
0.186
0.000
0.000
0.000
0.000
0.000
Meloxicam group
Before treatment
0.85 ± 0.13
123 ± 8.5
53 ± 4.7
0.132 ± 0.004
2.13 ± 0.11
68 ± 5.4
132 ± 5.4
After treatment
0.58 ± 0.21
98.1 ± 12.9
16.38 ± 3.5
0.069 ± 0.005
1.69 ± 0.19
82 ± 3.5
105 ± 4.7
t
3.723
3.517
14.093
5.506
4.856
5.239
13.069
P
0.005
0.007
0.000
0.000
0.001
0.001
0.000
Comparison of the two groups before treatment
t
15.74
7.292
3.17
8.95
4.848
10.548
5.745
P
0.000
0.000
0.011
0.000
0.001
0.000
0.000
Comparison of the two groups after treatment
t
11.959
10.409
9.833
4.25
4.013
12.444
9.21
P
0.000
0.000
0.000
0.002
0.003
0.000
0.000
Citation: Hu CX, Hu KY, Wang JF. Potential role of the compound Eucommia bone tonic granules in patients with osteoarthritis and osteonecrosis: A retrospective study. World J Clin Cases 2020; 8(1): 46-53